Lupin Limited, founded in 1968 by Dr. Desh Bandhu Gupta, is a leading Indian multinational pharmaceutical company headquartered in Mumbai. It ranks among the world’s top generic pharmaceutical companies, with a presence in over 100 countries and total revenue of US$2.36 billion in FY24. Lupin’s business spans the entire pharmaceutical value chain, including branded and generic formulations, active pharmaceutical ingredients (APIs), advanced drug delivery systems, and biotechnology. Key therapeutic areas include cardiovascular, diabetology, asthma, pediatrics, anti-infectives, and anti-tuberculosis, with a global leadership position in the anti-TB segment.

The company has a robust global footprint, with significant operations in the US (37% of global revenues, $891 million enterprise), Europe, Japan, Australia, and emerging markets like India, Brazil, Mexico, and South Africa. Its US subsidiary, Lupin Pharmaceuticals Inc., is the 4th largest generic player by prescriptions, leading in 46 of 140 marketed products. Lupin operates 15 state-of-the-art manufacturing facilities across India, the US, Brazil, and Mexico, and invests heavily in R&D, focusing on complex generics, biosimilars, and specialty drugs like inhalation and injectables. Strategic acquisitions, such as Medisol (France, 2023), Medquímica (Brazil, 2015), and Gavis/Novel (US, 2015), have bolstered its global reach and portfolio.

Lupin’s India business, contributing 34% of revenue, outperforms the market with a 3.4% share, driven by chronic therapies. The company emphasizes digital transformation, leveraging AI for innovation, and maintains a strong ESG framework. Despite challenges like regulatory hurdles (e.g., FDA warnings) and pricing pressures, Lupin has achieved double-digit growth, supported by a deep pipeline (154 ANDA filings pending FDA approval) and patient-centric initiatives like NovaShakti and Jeet. However, recent setbacks, such as the Myrbetriq patent litigation loss in 2025, pose risks. Lupin’s focus on innovation, affordability, and strategic expansion positions it for sustained growth in the global pharma landscape.